Amine salts of an integrin receptor antagonist
CA 2465416 A1 · Owner: Merck & Co. Inc. · Inventors: Yasuda, Nobuyoshi; Wells, Kenneth M.; Wang, Yaling
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Amine salts of 3-{2-oxo-3-3-(5,6,7,8-tetrahydro1,8naphthyridin-2-yl)propylimidazolidin-1-yl}-3-(6-methoxy-pyridin-3-yl)propionic acid are potent antagonists of the integrin .alpha.v.szlig.3 receptor and are useful for the prevention and/or treatment of osteoporosis and vascular restenosis as well , as conditions associated with excessive angiogenesis such as macular , degeneration, diabetic retinopathy atherosclerosis, inflammatory arthritis cancer, and metastatic tumor growth. The invention also relates to a process for the preparation of the novel salts as well as pharmaceutical compositions containing the salts and methods of using the salts.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 1, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 1, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 1, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.